Kexing Pharma Receives Ethical Approval for Phase II Study of SHEN26 COVID-19 Drug
China-based Kexing Pharmaceutical (SHA: 688136) has announced receiving ethical approval to conduct a Phase II...
Kintor Pharma’s GT20029 Shows Positive Results in Phase I Study for Androgenetic Alopecia and Acne
China-based Kintor Pharmaceutical Ltd (HKG: 9939) has announced positive results from a Phase I clinical...
FibroGen Sues Former Employees and Two Pharma Firms for Trade Secret Theft
US-based FibroGen Inc. has filed a lawsuit against two former employees, Liu Dong and Deng...
JS InnoPharm and Strategia Holdings Form JSI Ventures in Boston
Shanghai-based JS InnoPharm Ltd has announced an agreement with US firm Strategia Holdings LLC to...
Jianke.com Files for Hong Kong IPO with Focus on Chronic Disease Management
China-based smart healthcare service platform Jianke.com (Fangzhou Inc.) has filed for an initial public offering...
China’s First Gene Therapy for Deafness, RRG-003, Begins Clinical Study
RRG-003, an adeno-associated virus (AAV) gene therapy co-developed by China’s Shanghai Dingxin Gene Technology Co.,...
Shanghai Hosts Yangtze River Delta Alliance VBP Tender for 44 Drugs
Shanghai’s Sunshine Medical Procurement All-in-One (SMPA) has released a document indicating that the city will...
BeiGene to Present Final PFS Results for Brukinsa at ASH Meeting
China-based biotech BeiGene Inc. (HKG: 6160, SHA: 688235, NASDAQ: BGNE) has announced plans to present...
Kunshi Biotechnology and Puheng Technology Partner on 3D NAC-Organ Platform for CAR-Macrophage Screening
Kunshi Biotechnology (Shenzhen) Co., Ltd and Suzhou Puheng Technology Co., Ltd have entered into a...
Endoso Life Raises Pre-Series A Funding for High-End Medical Endoscope Development
Endoso Life, a Hangzhou-based developer of high-end medical endoscope systems and devices, has reportedly raised...
Vcanbio’s VUM02 Accepted for Review by China’s Center for Drug Evaluation
China-based Vcanbio Cell & Gene Engineering Corp., Ltd (SHA: 600645) has announced that the clinical...
Fosun Pharma’s Human Interferon Gamma Approved for New Indication by NMPA
Shanghai Fosun Pharmaceutical Group Co (SHA: 600196) has announced receiving another indication approval from the...
InnoCare Pharma’s Hibruka Receives HSA Approval for Mantle Cell Lymphoma in Singapore
China-based InnoCare Pharma (HKG: 9969, SHA: 688428) has announced receiving market approval from the Health...
Sun-Novo Pharma to Acquire MAH Rights for Azilsartan from Baiao Pharma
China-based Beijing Sun-Novo Pharmaceutical Research Co., Ltd (SHA: 688621) has announced plans to acquire the...
UB Biotechnology Secures Series A Funding for Flow Cytometry Platform
China-based in vitro diagnostics (IVD) maker UB Biotechnology (Zhejiang) Co., Ltd has reportedly raised “tens...
IASO Biotherapeutics Partners with Umoja Biopharma to Evaluate iCIL Platform
China-based biopharma IASO Biotherapeutics has announced a research agreement with US immuno-oncology company Umoja Biopharma,...
Shanghai Unveils Policies to Boost Global Biomedical R&D Hub
The Shanghai municipal government has released a set of policies and measures aimed at accelerating...
WuXi Biologics Launches Integrated Biologics CRDMO Center in Shanghai
China-based Contract Research, Development, and Manufacturing Organization (CRDMO) WuXi Biologics (HKG: 2269) has launched its...
Nona Biosciences Licenses HCAb Technology to Dragonfly Therapeutics
Nona Biosciences, a newly established wholly owned subsidiary of Harbour BioMed (HKG: 2142), has struck...
Salubris Pharmaceuticals’ SAL0119 Accepted for CDE Review in China
China’s Shenzhen Salubris Pharmaceuticals Co., Ltd (SHE: 002294) has announced that its clinical trial filing...